Primary Prevention of Cardiovascular Disease in Older Adults

Canadian Journal of Cardiology

Volumn 32, Issue 9, 2016, Pages 1074-1081

  Barry, Arden R ^a,b   O'Neill, Deirdre E ^c   Graham, Michelle M ^c  

^a Lower Mainland Pharmacy Services   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT;

ACUTE HEART INFARCTION; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET; DRUG WITHDRAWAL; FRAMINGHAM RISK SCORE; GENETIC HETEROGENEITY; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MYOPATHY; NEOPLASM; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; WEIGHT REDUCTION; AGED; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COGNITIVE DEFECT; DRUG INTERACTION; MEDICATION COMPLIANCE; MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION;

AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COGNITIVE DYSFUNCTION; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MEDICATION ADHERENCE; MUSCULAR DISEASES; NEOPLASMS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK ASSESSMENT; SMOKING CESSATION;

EID: 84964664187     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2016.01.032     Document Type: Review

References (46)

1. 1 Sardar, M.R., Badri, M., Prince, C.T., Seltzer, J., Kowey, P.R., Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Intern Med 174 (2014), 1868–1870.
2. 2 Konrat, C., Boutron, I., Trinquart, L., et al. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One, 7, 2012, e33559.
3. 3 Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:suppl 2 (2014), S1–S45.
4. 4 Genest, J., McPherson, R., Frohlich, J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol 25 (2009), 567–579.
5. 5 Johansen, M.E., Green, L.A., Statin use in very elderly individuals, 1999-2012. JAMA Intern Med 175 (2015), 1715–1716.
6. 6 Al-Omran, M., Mamdani, M.M., Lindsay, T.F., et al. Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study. J Vasc Surg 48 (2008), 607–612.
7. 7 Shepherd, J., Blauw, G.J., Murphy, M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002), 1623–1630.
8. 8 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
9. 9 Savarese, G., Gotto, A.M., Paolillo, S., et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol 62 (2013), 2090–2099.
10. 10 McGuinness, B., Craig, D., Bullock, R., Passmore, P., Statins for prevention of dementia. Cochrane Database Syst Rev(2), 2009, CD003160.
11. 11 Richardson, K., Schoen, M., French, B., et al. Statins and cognitive function: a systematic review. Ann Intern Med 159 (2013), 688–697.
12. 12 Swiger, K.J., Manalac, R.J., Blumenthal, R.S., Blaha, M.J., Martin, S.S., Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 88 (2013), 1213–1221.
13. 13 Macedo, A.F., Taylor, F.C., Casas, J.P., et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med, 12, 2014, 51.
14. 14 Ott, B.R., Daiello, L.A., Dahabreh, I.J., et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med 30 (2015), 348–358.
15. 15 Mancini, G.B., Baker, S., Bergeron, J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 27 (2011), 635–662.
16. 16 Sattar, N., Preiss, D., Murray, H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375 (2010), 735–742.
17. 17 Jackevicius, C.A., Mamdani, M., Tu, J.V., Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002), 462–467.
18. 18 Law, M., Rudnicka, A.R., Statin safety: a systematic review. Am J Cardiol 97 (2006), 52C–60C.
19. 19 Goh, I.X., How, C.H., Tavintharan, S., Cytochrome P450 drug interactions with statin therapy. Singapore Med J 54 (2013), 131–135.
20. 20 Holtzman, C.W., Wiggins, B.S., Spinler, S.A., Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26 (2006), 1601–1607.
21. 21 Burke, F.M., Red yeast rice for the treatment of dyslipidemia. Curr Atheroscler Rep, 17, 2015, 495.
22. 22 Kutner, J.S., Blatchford, P.J., Taylor, D.H., et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 175 (2015), 691–700.
23. 23 ClinicalTrials.gov. A Clinical Trial of STAtin Therapy For Reducing Events in the Elderly (STAREE). Available at: https://clinicaltrials.gov/ct2/show/NCT02099123. Accessed November 27, 2015.
24. 24 Go, A.S., Mozaffarian, D., Roger, V.L., et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129 (2014), e28–e292.
25. 25 MRC Working Party. Medical research council trial of treatment of hypertension in older adults: principal results. BMJ 304 (1992), 405–412.
26. 26 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (1991), 3255–3264.
27. 27 Perry, H.M., Davis, B.R., Price, T.R., et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 284 (2000), 465–471.
28. 28 Molander, L., Lövheim, H., Norman, T., Nordström, P., Gustafson, Y., Lower systolic blood pressure is associated with greater mortality in people aged 85 and older. J Am Geriatr Soc 56 (2008), 1853–1859.
29. 29 Beckett, N.S., Peters, R., Fletcher, A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 (2008), 1887–1898.
30. 30 The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
31. 31 Daskalopoulou, S.S., Rabi, D.M., Zarnke, K.B., et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 31 (2015), 549–568.
32. 32 Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
33. 33 James, P.A., Oparil, S., Carter, B.L., et al. 2014 Evidence-based guidelines for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
34. 34 Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 37:suppl 1 (2013), S1–S212.
35. 35 Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
36. 36 Ikeda, Y., Shimada, K., Teramoto, T., et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312 (2014), 2510–2520.
37. 37 ClinicalTrials.gov. Aspirin in reducing events in the elderly (ASPREE). Available at: https://clinicaltrials.gov/ct2/show/NCT01038583. Accessed November 27, 2015.
38. 38 Bell, A.D., Roussin, A., Cartier, R., et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol 27 (2011), S1–S59.
39. 39 Lightwood, J.M., Glantz, S.A., Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation 120 (2009), 1373–1379.
40. 40 LaCroix, A.Z., Omenn, G.S., Older adults and smoking. Clin Geriatr Med 8 (1992), 69–87.
41. 41 Iso, H., Date, C., Yamamoto, A., et al. Smoking cessation and mortality from cardiovascular disease among Japanese men and women: the JACC study. Am J Epidemiol 161 (2005), 170–179.
42. 42 Hupin, D., Roche, F., Gremeaux, V., et al. Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged ≥60 years: a systematic review and meta-analysis. Br J Sports Med 49 (2015), 1262–1267.
43. 43 Mozaffarian, D., Lemaitre, R.N., Kuller, L.H., et al. Cardiac benefits of fish consumption may depend on the type of fish meat consumed: the Cardiovascular Health Study. Circulation 107 (2003), 1372–1377.
44. 44 Estruch, R., Ros, E., Salas-Salvadó, J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368 (2013), 1279–1290.
45. 45 Ghaem Maralani, H.G., Tai, B.C., Wong, T.Y., et al. The prognostic role of body mass index on mortality amongst the middle-aged and elderly: a competing risk analysis. Diabetes Res Clin Pract 103 (2014), 42–50.
46. 46 Takata, Y., Ansai, T., Soh, I., et al. Association between body mass index and mortality in an 80-year-old population. J Am Geriatr Soc 55 (2007), 913–917.